Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 62 for “"Ivacaftor"”.

  1. Burden of Illness and Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in Cystic Fibrosis

    … a pharmacoeconomic evaluation of lumacaftor/ivacaftor in the treatment of CF. <strong></strong></p> <p><strong>Methods:</strong> The study was conducted in two parts. Part 1 involved a retrospective analysis using individuals in MEPS database with an International Classification of Diseases, …

    duquesne Repository record for Burden of Illness and Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in Cystic Fibrosis (opens in a new tab)

  2. Ο ρόλος του Kalydeco (Ivacaftor) στην αντιμετώπιση της κυστικής ίνωσης: Συστηματική ανασκόπηση

    … 2012 για το φάρμακο κυστικής ίνωσης Kalydeco® (Ivacaftor), σηματοδότησε μια σημαντική πρόοδο στη θεραπεία της ΚΙ, διότι πρόκειται για το πρώτο φάρμακο που στοχεύει στο μηχανισμό της νόσου και όχι στα συμπτώματά της. Με βάση τα προαναφερόμενα, η συγκεκριμένη εργασία μελετάει τα παραπάνω, τόσο …

    athens Repository record for Ο ρόλος του Kalydeco (Ivacaftor) στην αντιμετώπιση της κυστικής ίνωσης: Συστηματική ανασκόπηση (opens in a new tab)

  3. Dynamical Effects of Mutations and Ivacaftor Binding on the Cystic Fibrosis Transmembrane Conductance Regulator

    … small-molecule modulators, such as potentiators (ivacaftor) and correctors (lumacaftor, tezacaftor), have improved clinical outcomes, they often only partially restore CFTR function, and the precise atomistic mechanisms underlying their effects remain unclear.<br/>In this thesis, I employed …

    bristol Repository record for Dynamical Effects of Mutations and Ivacaftor Binding on the Cystic Fibrosis Transmembrane Conductance Regulator (opens in a new tab) Download PDF for Dynamical Effects of Mutations and Ivacaftor Binding on the Cystic Fibrosis Transmembrane Conductance Regulator (opens in a new tab)

  4. Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis

    … CF population. Recently Elexacaftor/Tezacaftor/Ivacaftor (ETI) was approved for use in up to 90% of people with CF. Our single center open-label observational cohort study aimed to explore the changes in dietary and metabolic outcomes with use of ETI. Methods: Participants underwent baseline …

    uab Repository record for Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis (opens in a new tab)

  5. Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation

    … consequences of CFTR dysfunction. The advent of ivacaftor offers the opportunity to evaluate the effect of restoration of CFTR function on CF lung disease and extrapulmonary manifestations. Global prevalence of the G551D mutation is 4%. Prevalance at Cork CF centre is 23%. Thus this work …

    cork Repository record for Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation (opens in a new tab)

  6. The Investigation of Quality of Life, Perceived Disease Severity, and Adherence in Patients with the G551D Mutation Receiving Ivacaftor Therapy

    … to three times a day for up to 20 minutes each. Ivacaftor is a new oral cystic fibrosis therapy for the treatment of CF approved specifically for patients with the G551D mutation in January of 2012, and is only available to fewer than 5% of the total CF population. Although this type of therapy …

    uab Repository record for The Investigation of Quality of Life, Perceived Disease Severity, and Adherence in Patients with the G551D Mutation Receiving Ivacaftor Therapy (opens in a new tab)

  7. Elexacaftor/Tezacaftor/Ivacaftor Prescription in Lung Transplant Recipients with Cystic Fibrosis in the US: A CFF Patient Registry Cross-Sectional Analysis

    Elexacaftor/tezacaftor/ivacaftor (ETI) has dramatically improved pulmonary and extrapulmonary manifestations of cystic fibrosis (CF). ETI clinical trials excluded lung transplant (LTx) recipients, and current post-transplant prescribing practices are not evidence-based. We sought to identify the …

    washington Repository record for Elexacaftor/Tezacaftor/Ivacaftor Prescription in Lung Transplant Recipients with Cystic Fibrosis in the US: A CFF Patient Registry Cross-Sectional Analysis (opens in a new tab)

  8. New treatment options for cystic fibrosis

    … disease processes. Three drugs, including ivacaftor, which has been approved by the United States Food and Drug Administration, and VX-809 and ataluren, which are still in clinical trial, have been shown to improve patient clinical measures. VX-809 targets the most prevalent CF mutation, …

    bu Repository record for New treatment options for cystic fibrosis (opens in a new tab)

  9. Exploiting Species Differences to Understand the Function and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator

    … channel. The licensing of the CFTR potentiator ivacaftor (VX-770, Vertex Pharmaceuticals Inc.), provided proof of concept for the use of small molecules to treat CF. However, the mechanism of action of ivacaftor is not well understood. Studies exploiting species differences in CFTR pharmacology …

    bristol Repository record for Exploiting Species Differences to Understand the Function and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator (opens in a new tab) Download PDF for Exploiting Species Differences to Understand the Function and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator (opens in a new tab)

  10. Η αξία της δοκιμασίας ιδρώτα στη μέτρηση της λειτουργικότητας της πρωτεΐνης CFTR στην κυστική ίνωση: Μια συστηματική ανασκόπηση

    … δικτύου, το vanzacaftor/tezacaftor/deutivacaftor επέφερε τη μεγαλύτερη μείωση χλωρίου (μέση διαφορά [MD] −51,78 mmol/L, 95% CI −60,23 έως −43,34, P-score 0,99), ακολουθούμενο από το elexacaftor/tezacaftor/ivacaftor (MD −46,18, −52,39 έως −39,98, 0,80), το ivacaftor (MD −35,42, 0,60) και …

    athens Repository record for Η αξία της δοκιμασίας ιδρώτα στη μέτρηση της λειτουργικότητας της πρωτεΐνης CFTR στην κυστική ίνωση: Μια συστηματική ανασκόπηση (opens in a new tab)

  11. Influencia de la detección fúngica en las exacerbaciones de los pacientes con Fibrosis quística y evolución tras la introducción de Elexacaftor/Tezacaftor/Ivacaftor

    … tras la introducción de Elexacaftor/Tezacaftor /Ivacaftor (ETI).Material y métodos: Se diseñó un estudio prospectivo en pacientes adultos (> 18 años) en seguimiento en la Unidad de FQ del Hospital Universitario Central de Asturias (HUCA), entre enero de 2021 y abril de 2022, con al menos una …

    oviedo Repository record for Influencia de la detección fúngica en las exacerbaciones de los pacientes con Fibrosis quística y evolución tras la introducción de Elexacaftor/Tezacaftor/Ivacaftor (opens in a new tab)

  12. Utilisation of CFTR orthologues to evaluate new therapies for cystic fibrosis

    … combination therapy elexacaftor-tezacaftor-ivacaftor was applied to heterologous cells. When compared with rescue by low temperature incubation, elexacaftor-tezacaftor-ivacaftor increased current flow through the channel and improved the thermostability of a sub-population of channels …

    bristol Repository record for Utilisation of CFTR orthologues to evaluate new therapies for cystic fibrosis (opens in a new tab) Download PDF for Utilisation of CFTR orthologues to evaluate new therapies for cystic fibrosis (opens in a new tab)

  13. Νεότερα φάρμακα για τη θεραπεία της κυστικής ίνωσης

    … Στην κλινική πράξη χρησιμοποιούνται, ο ενισχυτής Ivacaftor, σε παιδιά ≥ 4 μηνών με συγκεκριμένες μεταλλάξεις, ο συνδυασμός επιδιορθωτή με ενισχυτή Lumacaftor/Ivacaftor για ασθενείς ομοζυγώτες για την Phe508del ≥ 12 μηνών, ο 2ος συνδυασμός επιδιορθωτή με ενισχυτή Tezacaftor/Ivacaftor για παιδιά ≥ 6 …

    athens Repository record for Νεότερα φάρμακα για τη θεραπεία της κυστικής ίνωσης (opens in a new tab)

  14. Using registry data to estimate the effects of long-term treatment use in cystic fibrosis

    … by investigating two CF treatments: DNase and ivacaftor. DNase is a common CF treatment and generally, once started, it continues to be used indefinitely. Despite this, no studies have investigated its long-term effects. Estimating these effects using registry data is difficult due to …

    lshtm Repository record for Using registry data to estimate the effects of long-term treatment use in cystic fibrosis (opens in a new tab) Download PDF for Using registry data to estimate the effects of long-term treatment use in cystic fibrosis (opens in a new tab)

  15. A mixed methods study in cystic fibrosis following the widespread availability of elexacaftor/tezacaftor/ivacaftor. Understanding the impact of context change in long-term condition care

    … how the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) has shaped cystic fibrosis (CF) care. This pragmatic, mixed-methods Realist Evaluation examined how clinicians and people with CF (pwCF) made sense of and responded to this contextual change, focussing on adherence to inhaled …

    whiterose Download PDF for A mixed methods study in cystic fibrosis following the widespread availability of elexacaftor/tezacaftor/ivacaftor. Understanding the impact of context change in long-term condition care (opens in a new tab)

  16. Regulation of CFTR function and stability by phosphorylation and its membrane environment

    … CFTR function. Potentiator drugs, like ivacaftor, enhance CFTR function at the cell surface. I conducted biochemical experiments to find that high concentrations of ivacaftor non-specifically destabilized F508del-CFTR and other membrane proteins. This non-specific destabilization of …

    toronto-retro Repository record for Regulation of CFTR function and stability by phosphorylation and its membrane environment (opens in a new tab)

  17. Remodelado óseo en los pacientes con fibrosis quística en tratamiento con moduladores del canal regulador de la conductancia transmembrana

    … con moduladores del CFTR: lumacafator-ivacaftor (LUM/IVA), tezacaftor-ivacaftor (TEZ/IVA) o elexacaftor-tezacaftor-ivacaftor (ETI). Metodología: Estudio observacional prospectivo con evaluación basal y al año del tratamiento. Se midieron DMO en columna lumbar, cadera y cuello femoral …

    sevilla Repository record for Remodelado óseo en los pacientes con fibrosis quística en tratamiento con moduladores del canal regulador de la conductancia transmembrana (opens in a new tab)

  18. Role of the Lipid Environment and Cholesterol Content in the Function of CFTR Modulators

    … evaluated the effects of two CFTR modulators - Ivacaftor and Lumacaftor (and their combination, Orkambi) - on the folding of mutant CFTR hairpins, with a focus on whether these drugs can rescue the fold of the hairpins to the WT conformation. Finally, to gauge the importance of the membrane …

    toronto-retro Repository record for Role of the Lipid Environment and Cholesterol Content in the Function of CFTR Modulators (opens in a new tab)

Page 1 of 4